Adjuvant low-dose interleukin-2 (IL2) plus interferone-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC)

被引：0
|
作者：
Passalacqua, R.
Buzio, C.
Buti, S.
Labianca, R.
Porta, C.
Boni, C.
Rondini, E.
Camisa, R.
Sabbatini, R.
Artioli, F.
Caminiti, C.
机构：
[1] Ist Ospitalieri, Cremona, Italy
[2] Univ Parma, Parma, Italy
[3] Bergamo Hosp, Bergamo, Italy
[4] Policlin San Matteo, Pavia, Italy
[5] Arcispedale S Maria Nuova, Reggio Emilia, Italy
[6] Univ Hosp, Parma, Italy
[7] Univ Hosp, Modena, Italy
[8] Hosp Carpi, Carpi, MO, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA5028
引用
收藏
页数：1
相关论文
共 42 条
  • [1] Adjuvant low-dose interleukin-2 (IL2) plus interferon-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the italian oncology group for clinical research (GOIRC)
    Passalacqua, Rodolfo
    Buzio, Carlo
    Potenzoni, Domenico
    Buti, Sebastiano
    Labianca, Roberto
    Porta, Camillo
    Nastasi, Pino
    Rondini, Ermanno
    Camisa, Roberta
    Sabbatini, Roberto
    Artioli, Fabrizio
    Alberici, Federico
    Bongiovanni, Cristiano
    Pezzuolo, Debora
    Caminiti, Caterina
    ANNALS OF ONCOLOGY, 2007, 18 : 82 - 82
  • [2] Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-α (IFN-α) in Operable Renal Cell Carcinoma (RCC): A Phase III, Randomized, Multicentre Trial of the Italian Oncology Group for Clinical Research (GOIRC)
    Passalacqua, Rodolfo
    Caminiti, Caterina
    Buti, Sebastiano
    Porta, Camillo
    Camisa, Roberta
    Braglia, Luca
    Tomasello, Gianluca
    Vaglio, Augusto
    Labianca, Roberto
    Rondini, Ermanno
    Sabbatini, Roberto
    Nastasi, Giuseppe
    Artioli, Fabrizio
    Prati, Andrea
    Potenzoni, Michele
    Pezzuolo, Debora
    Oliva, Elena
    Alberici, Federico
    Buzio, Carlo
    JOURNAL OF IMMUNOTHERAPY, 2014, 37 (09) : 440 - 447
  • [3] Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-a (IFN-a) in Operable Renal Cell Carcinoma (RCC): A Phase III, Randomized, Multicentre Trial of the Italian Oncology Group for Clinical Research (GOIRC) (vol 37, pg 440, 2014)
    Passalacqua, R.
    Caminiti, C.
    Buti, S.
    JOURNAL OF IMMUNOTHERAPY, 2015, 38 (05) : 216 - 216
  • [4] Phase III, randomized, multicentre trial of maintenance biotherapy with interleukin-2 (IL-2) and interferon-alpha (IFN) for metastatic renal cell cancer (RCC)
    Passalacqu, R
    Buzio, C
    Dalla Chiesa, M
    Camisa, R
    Porta, C
    Labianca, R
    Frassoldati, A
    Buti, S
    Pezzuolo, D
    Tomasello, G
    Caminiti, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 404S - 404S
  • [5] PHASE III, RANDOMISED, MULTICENTRE, CONTROLLED TRIAL OF MAINTENANCE BIOTHERAPY FOR METASTATIC RENAL CELL CANCER WITH INTERLEUKIN-2 AND INTERFERON-ALPHA-2A. A STUDY OF THE ITALIAN ONCOLOGICAL GROUP FOR CLINICAL RESEARCH (GOIRC)
    Passalacqua, R.
    Buzio, C.
    Porta, C.
    Labianca, R.
    Frassoldati, A.
    Buti, S.
    Pezzuolo, D.
    Vaglio, A.
    Tomasello, G. L.
    Dalla Chiesa, M.
    Camisa, R.
    Caminiti, C.
    ANNALS OF ONCOLOGY, 2004, 15 : 98 - 98
  • [6] Bevacizumab plus immunotherapy, with interleukin-2 (IL-2) and interferone-α (IFN-α), plus chemotherapy (BIC), in patients with metastatic renal cell cancer (mRCC).: Dose-finding/phase II trial
    Buti, Sebastiano
    Lazzarelli, Silvia
    Simonelli, Cecilia
    Venturini, Silvia
    Spazzapan, Simon
    Lo Re, Giovanni
    Mattioli, Rodolfo
    Chiesa, Matteo Dalla
    Brighenti, Matteo
    Mazza, Giancarlo
    Passalacqua, Rodolfo
    ANNALS OF ONCOLOGY, 2007, 18 : 81 - 81
  • [7] Phase II clinical trial of low-dose interleukin-2, interferon-alpha, and low-dose tegafur uracil therapy for advanced renal cell cancer.
    Kato, Tomoyuki
    Iwamura, Masatsugu
    Fujita, Tetsuo
    Saito, Seiichi
    Ohshiro, Yoshinori
    Imai, Tomoyuki
    Kawata, Nozomu
    Tomita, Yoshihiko
    Sejima, Takehiro
    Kishida, Takeshi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [8] A phase II study of chronic low dose of interleukin-2 (IL2) and α-interferon (IFN-α) in metastatic renal cell carcinoma (MRCC)
    Cengarle, R
    Buzio, C
    Pavone, L
    Santi, R
    Todeschini, R
    Caminiti, C
    Porta, C
    Bidin, L
    Frassoldati, A
    Contu, A
    Passalacqua, R
    ANNALS OF ONCOLOGY, 2000, 11 : 31 - 31
  • [9] Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-α for metastatic renal cell cancer
    Rodolfo Passalacqua
    Carlo Buzio
    Sebastiano Buti
    Camillo Porta
    Roberto Labianca
    Debora Pezzuolo
    Roberta Camisa
    Roberto Sabbatini
    Luigi Benecchi
    Caterina Messina
    Rita Cengarle
    Augusto Vaglio
    Matteo Dalla Chiesa
    Gianluca Tomasello
    Caterina Caminiti
    Cancer Immunology, Immunotherapy, 2010, 59 : 553 - 561
  • [10] Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-α for metastatic renal cell cancer
    Passalacqua, Rodolfo
    Buzio, Carlo
    Buti, Sebastiano
    Porta, Camillo
    Labianca, Roberto
    Pezzuolo, Debora
    Camisa, Roberta
    Sabbatini, Roberto
    Benecchi, Luigi
    Messina, Caterina
    Cengarle, Rita
    Vaglio, Augusto
    Dalla Chiesa, Matteo
    Tomasello, Gianluca
    Caminiti, Caterina
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (04) : 553 - 561
12345